CD99 Chimeric antigen receptor T-Cell Therapy in the treatment of adult Rhabdomyosarcoma: A case report and literature review
•CD99 is overexpressed in various malignant tumors, including Ewing's sarcoma and hematological cancers. CAR-T cell therapy was used for targeted treatment in an adult patient with malignant peripheral schwannoma and embryonal rhabdomyosarcoma. Despite postoperative complications and intoleranc...
Uloženo v:
| Vydáno v: | Current problems in cancer. Case reports Ročník 19; s. 100383 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Elsevier Inc
01.09.2025
Elsevier |
| Témata: | |
| ISSN: | 2666-6219, 2666-6219 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | •CD99 is overexpressed in various malignant tumors, including Ewing's sarcoma and hematological cancers. CAR-T cell therapy was used for targeted treatment in an adult patient with malignant peripheral schwannoma and embryonal rhabdomyosarcoma. Despite postoperative complications and intolerance to radiation therapy, CAR-T cell therapy targeting CD99 is well tolerated and stabilized the disease for 13 months, highlighting its potential as a novel treatment for refractory sarcomas.
CD99 is a transmembrane protein overexpressed in tumor tissues, particularly in Ewing’s sarcoma. Recent studies have highlighted distinct patterns of CD99 expression in various malignancies, including gliomas, osteosarcoma, and breast and pancreatic cancers. CD99 is also expressed in hematopoietic cell lines, with differential expression in hematological malignancies such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia, suggesting its potential as a therapeutic target.
We report the case of an adult patient with a malignant peripheral nerve sheath tumor of the left thigh with embryonal rhabdomyosarcoma and adenoid differentiation. The patient underwent R0 resection surgery but experienced complications, including infection and poor wound healing, and was unable to tolerate radiotherapy. Postoperative pathological analysis revealed CD99 positivity. Given the lack of response to conventional treatments, the patient underwent CD99-targeted chimeric antigen receptor T (CAR-T) cell therapy. The therapy was well-tolerated, with only mild cytokine release syndrome (CRS), and resulted in disease stabilization over 13 months of follow-up.
This case demonstrates the potential of CD99-targeted CAR-T cell therapy as a novel and effective treatment for adult rhabdomyosarcoma. These findings suggest that CD99-CAR-T cell therapy warrants further investigation as a therapeutic option for refractory sarcomas. |
|---|---|
| AbstractList | •CD99 is overexpressed in various malignant tumors, including Ewing's sarcoma and hematological cancers. CAR-T cell therapy was used for targeted treatment in an adult patient with malignant peripheral schwannoma and embryonal rhabdomyosarcoma. Despite postoperative complications and intolerance to radiation therapy, CAR-T cell therapy targeting CD99 is well tolerated and stabilized the disease for 13 months, highlighting its potential as a novel treatment for refractory sarcomas.
CD99 is a transmembrane protein overexpressed in tumor tissues, particularly in Ewing’s sarcoma. Recent studies have highlighted distinct patterns of CD99 expression in various malignancies, including gliomas, osteosarcoma, and breast and pancreatic cancers. CD99 is also expressed in hematopoietic cell lines, with differential expression in hematological malignancies such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia, suggesting its potential as a therapeutic target.
We report the case of an adult patient with a malignant peripheral nerve sheath tumor of the left thigh with embryonal rhabdomyosarcoma and adenoid differentiation. The patient underwent R0 resection surgery but experienced complications, including infection and poor wound healing, and was unable to tolerate radiotherapy. Postoperative pathological analysis revealed CD99 positivity. Given the lack of response to conventional treatments, the patient underwent CD99-targeted chimeric antigen receptor T (CAR-T) cell therapy. The therapy was well-tolerated, with only mild cytokine release syndrome (CRS), and resulted in disease stabilization over 13 months of follow-up.
This case demonstrates the potential of CD99-targeted CAR-T cell therapy as a novel and effective treatment for adult rhabdomyosarcoma. These findings suggest that CD99-CAR-T cell therapy warrants further investigation as a therapeutic option for refractory sarcomas. Highlight•CD99 is overexpressed in various malignant tumors, including Ewing's sarcoma and hematological cancers. CAR-T cell therapy was used for targeted treatm ent in an adult patient with malignant peripheral schwannoma and embryonal rhabdomyosarcoma. Despite postoperative complications and intolerance to radiation therapy, CAR-T cell therapy targeting CD99 is well tolerated and stabilized the disease for 13 months, highlighting its potential as a novel treatment for refractory sarcomas. Background: CD99 is a transmembrane protein overexpressed in tumor tissues, particularly in Ewing’s sarcoma. Recent studies have highlighted distinct patterns of CD99 expression in various malignancies, including gliomas, osteosarcoma, and breast and pancreatic cancers. CD99 is also expressed in hematopoietic cell lines, with differential expression in hematological malignancies such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia, suggesting its potential as a therapeutic target. Case Presentation: We report the case of an adult patient with a malignant peripheral nerve sheath tumor of the left thigh with embryonal rhabdomyosarcoma and adenoid differentiation. The patient underwent R0 resection surgery but experienced complications, including infection and poor wound healing, and was unable to tolerate radiotherapy. Postoperative pathological analysis revealed CD99 positivity. Given the lack of response to conventional treatments, the patient underwent CD99-targeted chimeric antigen receptor T (CAR-T) cell therapy. The therapy was well-tolerated, with only mild cytokine release syndrome (CRS), and resulted in disease stabilization over 13 months of follow-up. Conclusions: This case demonstrates the potential of CD99-targeted CAR-T cell therapy as a novel and effective treatment for adult rhabdomyosarcoma. These findings suggest that CD99-CAR-T cell therapy warrants further investigation as a therapeutic option for refractory sarcomas. |
| ArticleNumber | 100383 |
| Author | Li, Ming Wu, Qin Li, Hui Wei, Xinyu Zhou, Meng Zhu, Ming Xiao, Yi Wu, Huixian Yin, Mengqing Long, Ping Zhu, Haichuan Zhang, Tongcun Feng, Lei |
| Author_xml | – sequence: 1 givenname: Hui orcidid: 0000-0001-8260-4841 surname: Li fullname: Li, Hui organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 2 givenname: Ping surname: Long fullname: Long, Ping organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 3 givenname: Xinyu surname: Wei fullname: Wei, Xinyu organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 4 givenname: Meng surname: Zhou fullname: Zhou, Meng organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 5 givenname: Mengqing surname: Yin fullname: Yin, Mengqing organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 6 givenname: Huixian surname: Wu fullname: Wu, Huixian organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 7 givenname: Haichuan surname: Zhu fullname: Zhu, Haichuan organization: College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 8 givenname: Ming surname: Zhu fullname: Zhu, Ming organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 9 givenname: Lei surname: Feng fullname: Feng, Lei organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 10 givenname: Ming surname: Li fullname: Li, Ming organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 11 givenname: Qin surname: Wu fullname: Wu, Qin organization: Department of Hematology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 12 givenname: Tongcun surname: Zhang fullname: Zhang, Tongcun email: zhangtongcun@wust.edu.cn organization: College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, Hubei, 430000, China – sequence: 13 givenname: Yi surname: Xiao fullname: Xiao, Yi email: yixiao@tjh.tjmu.edu.cn organization: Department of Hematology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, 430000, China |
| BookMark | eNqFkVFr1TAUx4tMcM59Al_yBXpN0jZtFYVR3RwMBtv1OZwmJ7upbVOSXOU--N1Nd0VEGHtJwiH_X3LO73V2MrsZs-wtoxtGmXg3bNSilN9wyqtUoUVTvMhOuRAiF5y1J_-cX2XnIQyUppuMtXV5mv3qPrct6XZ2Qm8VgTnaB5yJR4VLdJ5s8w7HkWx36GE5EDuTuEMSPUKccI7EGQJ6P0Zyt4Neu-ngAnjlJnhPLoiCgAm1OB8TWZPRxoSJe79Wf1j8-SZ7aWAMeP5nP8u-XX7Zdl_zm9ur6-7iJldlXcS85Fhp3hrBhOl7plVf6RrXpYIGQIsGRGN4UWOpWUFbqgU1aQyNoQaoYcVZdn3kageDXLydwB-kAysfC84_SPDRqhGlqVVRa9anqCoF1g22YKjWquaqZZomVnFkKe9C8Gj-8hiVqxA5yEchchUij0JS6uMxhanN1LqXQVmcFWqbZh3TP-wz-U__5dVoZ6tg_I4HDIPb-zlNUDIZuKTyflW-GudVsl1UK-DD04Bnn_8NepvA5g |
| Cites_doi | 10.1002/jbmr.2141 10.1016/j.jmb.2021.167402 10.1038/s41598-021-94588-5 10.1007/s12079-017-0445-z 10.1073/pnas.76.12.6552 10.1096/fj.02-0049fje 10.1016/j.ijrobp.2024.10.016 10.1158/2159-8290.CD-18-0442 10.15252/emmm.202216001 |
| ContentType | Journal Article |
| Copyright | 2025 The Author(s) The Author(s) |
| Copyright_xml | – notice: 2025 The Author(s) – notice: The Author(s) |
| DBID | 6I. AAFTH AAYXX CITATION DOA |
| DOI | 10.1016/j.cpccr.2025.100383 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-6219 |
| EndPage | 100383 |
| ExternalDocumentID | oai_doaj_org_article_f7c37d1bf0fc46e78e9af0ddc72c91d0 10_1016_j_cpccr_2025_100383 S2666621925000353 1_s2_0_S2666621925000353 |
| GroupedDBID | .1- .FO 0R~ 1P~ AAEDW AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL Z5R 6I. AAFTH AAYXX CITATION |
| ID | FETCH-LOGICAL-c473t-42e5d29f616fbb1dcb5d7eb5d75a8aad68a68f237e4d13090d60f3838f0fa0f13 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001547420400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2666-6219 |
| IngestDate | Fri Oct 03 12:53:18 EDT 2025 Sat Nov 29 07:30:04 EST 2025 Sat Oct 11 16:51:07 EDT 2025 Sat Oct 11 11:50:30 EDT 2025 Sat Oct 11 07:32:49 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Immunotherapy CD99 CAR-T cell therapy Rhabdomyosarcoma Malignant peripheral nerve sheath tumor |
| Language | English |
| License | This is an open access article under the CC BY-NC license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c473t-42e5d29f616fbb1dcb5d7eb5d75a8aad68a68f237e4d13090d60f3838f0fa0f13 |
| ORCID | 0000-0001-8260-4841 |
| OpenAccessLink | https://doaj.org/article/f7c37d1bf0fc46e78e9af0ddc72c91d0 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f7c37d1bf0fc46e78e9af0ddc72c91d0 crossref_primary_10_1016_j_cpccr_2025_100383 elsevier_sciencedirect_doi_10_1016_j_cpccr_2025_100383 elsevier_clinicalkeyesjournals_1_s2_0_S2666621925000353 elsevier_clinicalkey_doi_10_1016_j_cpccr_2025_100383 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-09-01 |
| PublicationDateYYYYMMDD | 2025-09-01 |
| PublicationDate_xml | – month: 09 year: 2025 text: 2025-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Current problems in cancer. Case reports |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Alberti, Bernard, Rouquette-Jazdanian, Pelassy, Pourtein, Aussel (bib0004) 2002; 16 Levy, Dilley, Fox, Warnke (bib0002) 1979; 76 Romero, Hattori, Ali, Ketavarapu, Koide, Park (bib0005) 2022; 434 Pasello, Manara, Scotlandi (bib0006) 2018; 12 Mansur (bib0009) 2025; 121 Mattisson, Danielsson, Hammond, Davies, Gallant, Nordlund (bib0003) 2021; 11 Meister, Groot Koerkamp, de Souza, Breunis, Frazer-Mendelewska, Brok (bib0001) 2022; 14 Majzner, Mackall (bib0008) 2018; 8 Sciandra, Marino, Manara, Guerzoni, Grano, Oranger (bib0007) 2014; 29 Romero (10.1016/j.cpccr.2025.100383_bib0005) 2022; 434 Alberti (10.1016/j.cpccr.2025.100383_bib0004) 2002; 16 Meister (10.1016/j.cpccr.2025.100383_bib0001) 2022; 14 Levy (10.1016/j.cpccr.2025.100383_bib0002) 1979; 76 Majzner (10.1016/j.cpccr.2025.100383_bib0008) 2018; 8 Pasello (10.1016/j.cpccr.2025.100383_bib0006) 2018; 12 Mattisson (10.1016/j.cpccr.2025.100383_bib0003) 2021; 11 Sciandra (10.1016/j.cpccr.2025.100383_bib0007) 2014; 29 Mansur (10.1016/j.cpccr.2025.100383_bib0009) 2025; 121 |
| References_xml | – volume: 29 start-page: 1295 year: 2014 end-page: 1309 ident: bib0007 article-title: CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2 publication-title: J. Bone Miner. Res.: Offic. J. Am. Soc. Bone Miner. Res. – volume: 434 year: 2022 ident: bib0005 article-title: High-valency anti-CD99 antibodies toward the treatment of T cell acute lymphoblastic leukemia publication-title: J. Mol. Biol. – volume: 11 year: 2021 ident: bib0003 article-title: Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99 publication-title: Sci. Rep. – volume: 8 start-page: 1219 year: 2018 end-page: 1226 ident: bib0008 article-title: Tumor antigen escape from CAR T-cell therapy publication-title: Cancer Discov. – volume: 121 start-page: 11 year: 2025 ident: bib0009 article-title: The challenge of local control in group III Rhabdomyosarcoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 12 start-page: 55 year: 2018 end-page: 68 ident: bib0006 article-title: CD99 at the crossroads of physiology and pathology publication-title: J. Cell Commun. Sign. – volume: 14 year: 2022 ident: bib0001 article-title: Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes publication-title: EMBO Mol. Med. – volume: 16 start-page: 1946 year: 2002 end-page: 1948 ident: bib0004 article-title: CD99 isoforms expression dictates T cell functional outcomes publication-title: FASEB J.: Offic. Public. Federat. Am. Societ. Experim. Biol. – volume: 76 start-page: 6552 year: 1979 end-page: 6556 ident: bib0002 article-title: A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 29 start-page: 1295 issue: 5 year: 2014 ident: 10.1016/j.cpccr.2025.100383_bib0007 article-title: CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2 publication-title: J. Bone Miner. Res.: Offic. J. Am. Soc. Bone Miner. Res. doi: 10.1002/jbmr.2141 – volume: 434 issue: 5 year: 2022 ident: 10.1016/j.cpccr.2025.100383_bib0005 article-title: High-valency anti-CD99 antibodies toward the treatment of T cell acute lymphoblastic leukemia publication-title: J. Mol. Biol. doi: 10.1016/j.jmb.2021.167402 – volume: 11 issue: 1 year: 2021 ident: 10.1016/j.cpccr.2025.100383_bib0003 article-title: Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99 publication-title: Sci. Rep. doi: 10.1038/s41598-021-94588-5 – volume: 12 start-page: 55 issue: 1 year: 2018 ident: 10.1016/j.cpccr.2025.100383_bib0006 article-title: CD99 at the crossroads of physiology and pathology publication-title: J. Cell Commun. Sign. doi: 10.1007/s12079-017-0445-z – volume: 76 start-page: 6552 issue: 12 year: 1979 ident: 10.1016/j.cpccr.2025.100383_bib0002 article-title: A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.76.12.6552 – volume: 16 start-page: 1946 issue: 14 year: 2002 ident: 10.1016/j.cpccr.2025.100383_bib0004 article-title: CD99 isoforms expression dictates T cell functional outcomes publication-title: FASEB J.: Offic. Public. Federat. Am. Societ. Experim. Biol. doi: 10.1096/fj.02-0049fje – volume: 121 start-page: 11 issue: 1 year: 2025 ident: 10.1016/j.cpccr.2025.100383_bib0009 article-title: The challenge of local control in group III Rhabdomyosarcoma publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2024.10.016 – volume: 8 start-page: 1219 issue: 10 year: 2018 ident: 10.1016/j.cpccr.2025.100383_bib0008 article-title: Tumor antigen escape from CAR T-cell therapy publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-0442 – volume: 14 issue: 10 year: 2022 ident: 10.1016/j.cpccr.2025.100383_bib0001 article-title: Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes publication-title: EMBO Mol. Med. doi: 10.15252/emmm.202216001 |
| SSID | ssj0002511974 |
| Score | 2.302633 |
| Snippet | •CD99 is overexpressed in various malignant tumors, including Ewing's sarcoma and hematological cancers. CAR-T cell therapy was used for targeted treatment in... Highlight•CD99 is overexpressed in various malignant tumors, including Ewing's sarcoma and hematological cancers. CAR-T cell therapy was used for targeted... Background: CD99 is a transmembrane protein overexpressed in tumor tissues, particularly in Ewing’s sarcoma. Recent studies have highlighted distinct patterns... |
| SourceID | doaj crossref elsevier |
| SourceType | Open Website Index Database Publisher |
| StartPage | 100383 |
| SubjectTerms | CAR-T cell therapy CD99 Hematology, Oncology, and Palliative Medicine Immunotherapy Malignant peripheral nerve sheath tumor Rhabdomyosarcoma |
| Title | CD99 Chimeric antigen receptor T-Cell Therapy in the treatment of adult Rhabdomyosarcoma: A case report and literature review |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666621925000353 https://www.clinicalkey.es/playcontent/1-s2.0-S2666621925000353 https://dx.doi.org/10.1016/j.cpccr.2025.100383 https://doaj.org/article/f7c37d1bf0fc46e78e9af0ddc72c91d0 |
| Volume | 19 |
| WOSCitedRecordID | wos001547420400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2666-6219 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511974 issn: 2666-6219 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2666-6219 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511974 issn: 2666-6219 databaseCode: M~E dateStart: 20200101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxFMsL82BIxGx4_jBrSytONAKwSL1Zjl-qIu2m1WzVOoBfjtjO1ktEqIXLjlEsSf5Jp6HZvyZkNdtYqlTWladFqri2urKskZX0qG_idRhXpRJXD_J01N1dqY_7x31lXrCCj1wAe5tlK6Rnnaxjo6LIFXQNtbeO8mcpj5n6xj17CVTyQazXB7jE81QbuhyG-cSAyhrU2tAo5o_XFFm7N_zSHte5vg-uTeGh3BYXusBuRXWD8mdk7EA_oj8nH_QGubny1xoAYQlsWkCmq2wwewZFtU8rFawKFwBsFwDBniw6yaHPkJm3IAv57bz_cV1P-Cf3l_Yd3AIDj0alCICzuxhtaNchrLD5TH5dny0mH-sxhMUKsdls604C61nOgoqYtdR77rWy5AurVXWeqGsUJE1MnCPzkzXXtQRkVGItq0jbZ6Qg3W_Dk8JcEepEE5r2SZWNK5pE51TLNQoAMXMyJsJTLMpRBlm6iD7bjL2JmFvCvYz8j4Bvns0sVznG6h7M-re3KT7GeGTusy0kRRNH060_Lds-bdhYRiX72CoGZipzVeMXoRAm87aXHLFkWI3coxQSuRxk8hn_-Nzn5O7acrS4faCHGwvf4SX5La72i6Hy1d5AeD15NfRbzRPDLE |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CD99+Chimeric+antigen+receptor+T-Cell+Therapy+in+the+treatment+of+adult+Rhabdomyosarcoma%3A+A+case+report+and+literature+review&rft.jtitle=Current+problems+in+cancer.+Case+reports&rft.au=Li%2C+Hui&rft.au=Long%2C+Ping&rft.au=Wei%2C+Xinyu&rft.au=Zhou%2C+Meng&rft.date=2025-09-01&rft.issn=2666-6219&rft.eissn=2666-6219&rft.volume=19&rft.spage=100383&rft.epage=100383&rft_id=info:doi/10.1016%2Fj.cpccr.2025.100383&rft.externalDBID=ECK1-s2.0-S2666621925000353&rft.externalDocID=1_s2_0_S2666621925000353 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26666219%2FS2666621924X00071%2Fcov150h.gif |